Venetoclax in Combination With ASTX727

Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
120 patients (estimated)
Sponsors
National Cancer Institute (NCI)
Tags
BCL-2 Inhibitor, Chemotherapy, Hypomethylating Agents (HMA)
Trial Type
Treatment
Last Update
1 week ago
SparkCures ID
1542
NCT Identifier
NCT05600894

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.